This presentation demonstrates the efficacy of Symprove which has been confirmed in a randomised, double-blind, placebo-controlled study by King’s College Hospital

1. + Probiotic efficacy
A probiotic product not only has to reach the gut, it also has to
do something beneficial once it arrives
There is a rationale for the use of probiotics in reducing IBS
symptoms but rigorous clinical testing has been lacking
The efficacy of Symprove has been confirmed in a randomised,
double-blind, placebo-controlled study by King’s College Hospital
1

2. +
Probiotics are
classed as a food, so
trials don’t need to
be as rigorous as
drugs
This was one of the
first studies to
address the efficacy
of a probiotic using
standards equivalent
to a drug trial
186 IBS sufferers,
mostly moderate to
severe, received a
daily dose of
Symprove or an
identical placebo
liquid for 3 months
2
Study Protocol

3. +
Symprove had an effect on:
3
3
Overall symptom severity - Achieved benefit in 60% of participants.
Just over a quarter had minimal or no symptoms at all at week 12
Bloating - Although some improvement was observed, it did not reach statistical significance.
As the study was not powered to demonstrate bloating, no firm conclusion may be made.
Bowel habit - Patients report an objectively measurable improvement in their satisfaction with
their bowel habit – both constipation and diarrhoea – which is unusual in IBS treatments
Pain - Importantly, there was a significant improvement in pain in the Symprove
group; considered the most common and most dominating IBS symptom
Study Results

4. +
The severity of the symptoms of IBS is normally plotted on a
scale up to 500. Before taking part, the average scores for the
participants was about 300
At the end of the study, those taking the placebo went down
to 270. However, the average score for those taking the active
drink dropped far more, to 240
When you consider that control subjects, who do not have IBS,
when tested score about 75, it shows you how significant a
reduction this was
Symptom
severity was
measured using
IBS-symptoms
severity score:
4
Study Results

5. +
5
Study Results
The significant change in
pain score is important as
pain is regarded as the key
measure for patient health

6. +
6
Study Results
Patients report an objectively
measurable improvement in
their satisfaction with their
bowel habit (constipation and
diarrhoea)

7. +
7
Study Results
Significant
improvement was
achieved in 4 weeks
Improvement
continued through
the full 12 weeks
Results show that this
multi-strain probiotic is
safe, well-tolerated and
efficacious in improving
overall symptom severity
in patients with IBS

8. +
8
Conclusion
1. Symprove was demonstrated
to IMPROVE the symptoms of
patients with IBS using a validated
symptom severity score
2. Symprove was shown to be safe
3. Symprove was shown to be
well tolerated